Skip to main content
Premium Trial:

Request an Annual Quote

Law Firm Says Suit Filed Against Affymetrix for Restating Earnings

NEW YORK (GenomeWeb News) – A law firm yesterday said that a shareholder derivative complaint has been filed against Affymetrix and certain past and present executive directors in a US District Court.
It wasn't immediately clear if the case the firm mentioned is the suit, filed Aug. 30 in California, that accuses several current and former officials at Affymetrix of a “gross breach of fiduciary duties” and claims these officials “improperly backdate[d] dozens of grants of Affymetrix stock options” to Affy CEO Stephen Fodor and other executives in violation of generally accepted accounting principles.
Calls placed to Affymetrix, based in Santa Clara, Calif., or to Keller Rohrback, based in Seattle, were not immediately returned.
On Aug. 30, Affymetrix amended its financial results for the quarter ending Mar. 31, and said the previous information “should no longer be relied upon.”

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.